Beckman Coulter, Hach Company Combine Particle Characterization and Counting Businesses - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Beckman Coulter, Hach Company Combine Particle Characterization and Counting Businesses



Beckman Coulter Life Sciences, a Danaher Corporation-owned life science company, is combining its particle characterization business with the particle counting business from Hach Company, another Danaher company. The move brings together Beckman Coulter’s knowledge in cell viability, particle sizing, and particle analysis with Hach’s experience in air and liquid particle counting, according to a Beckman Coulter press statement.

In some countries, the transition is subject to completing consultation and/or information with certain employee representative bodies. Personnel from the particle counting business of Hach will transition into the Beckman Coulter Life Sciences business to work with the Beckman Coulter particle characterization team.

Source: Beckman Coulter Life Sciences

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here